VIVS Latest Press Releases

-- October 21, 2026 --

VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling Globe Newswire 8:05 AM

-- October 7, 2026 --

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods Globe Newswire 8:05 AM

-- September 16, 2026 --

VivoSim Labs Unveils New NAMkind Drug Toxicity Data at EUROTOX 2026, Demonstrating Predictive Superiority in Liver and Gastrointestinal Safety Across Small Molecules and ADCs Globe Newswire 8:05 AM

-- September 1, 2026 --

VivoSim Labs to Add Rat Liver Model to NAMkind Platform Globe Newswire 8:05 AM

-- August 6, 2026 --

VivoSim Provides Financial and Listing Compliance Update Globe Newswire 8:05 AM

-- July 21, 2026 --

VivoSim Enters China with First Commercial Sales of NAMkind Toxicology Screening and Efficacy Testing Services Globe Newswire 8:05 AM

-- July 16, 2026 --

VivoSim Announces Pricing of $4.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules with a Single Healthcare Focused Institutional Investor Globe Newswire 8:30 AM

-- July 15, 2026 --

Three Biotechs Deliver Catalysts to Watch Globe Newswire 10:42 AM

VivoSim Receives $5M Milestone Payment from Eli Lilly; Provides Guidance That It Expects Revenue Growth of 500%+ in FY2027 Globe Newswire 8:05 AM

-- June 29, 2026 --

VivoSim Presents Data Showing Superiority to Competition in NAM Liver Tox Prediction at European Toxicology Meeting Globe Newswire 8:05 AM

Market Data Delayed 15 Minutes